Cargando…

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

PURPOSE: Afatinib, an oral irreversible ErbB family blocker, undergoes minimal metabolism by non-enzyme-catalysed adduct formation with proteins or nucleophilic small molecules and is predominantly non-renally excreted via the entero-hepatic system. This trial assessed whether mild or moderate hepat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnell, David, Buschke, Susanne, Fuchs, Holger, Gansser, Dietmar, Goeldner, Rainer-Georg, Uttenreuther-Fischer, Martina, Stopfer, Peter, Wind, Sven, Petersen-Sylla, Marc, Halabi, Atef, Koenen, Rüdiger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112049/ https://www.ncbi.nlm.nih.gov/pubmed/24906422 http://dx.doi.org/10.1007/s00280-014-2484-y

Ejemplares similares

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
por: Wiebe, Sabrina, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
por: Gordon, Michael S., et al.
Publicado: (2012)

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
por: Awada, A. H., et al.
Publicado: (2012)

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail
por: Stopfer, Peter, et al.
Publicado: (2017)

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors
por: Spicer, James, et al.
Publicado: (2016)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
por: Marshall, John, et al.
Publicado: (2012)

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin
por: Stopfer, P, et al.
Publicado: (2016)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
por: Gunzer, Katharina, et al.
Publicado: (2016)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer
por: Martin, Nicolas, et al.
Publicado: (2018)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
por: Schuler, Martin, et al.
Publicado: (2012)

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
por: Lin, Nancy U., et al.
Publicado: (2012)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
por: Desai, Amit, et al.
Publicado: (2016)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions
por: Stopfer, Peter, et al.
Publicado: (2018)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
por: Yasaka, Masahiro, et al.
Publicado: (2017)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
por: Zhang, Li, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study
por: Chattopadhyay, Niladri, et al.
Publicado: (2019)

“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
por: Yamada, Masanori, et al.
Publicado: (2013)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
por: Perera, Vidya, et al.
Publicado: (2022)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Validation of the Argentine version of the Memory Binding Test (MBT) for Early Detection of Mild Cognitive Impairment
por: Roman, Fabian, et al.
Publicado: (2016)

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study
por: Dahlke, Marion, et al.
Publicado: (2015)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
por: Nakao, Keiko, et al.
Publicado: (2019)

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
por: Smith, William B., et al.
Publicado: (2012)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
por: Marcinak, John, et al.
Publicado: (2018)

New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment
por: Tellone, Valeria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mn4inskj16er756ut76n4uhua6